ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML.
Mario TiribelliAntonella GerominMargherita CavallinSara Di GiustoErica SimeoneRenato FaninDaniela DamianiPublished in: European journal of haematology (2017)
Our data confirm a negative impact of ABCG2 and CD200 overexpression also in AML patients considered at favorable risk according to ELN cytogenetic/molecular classification.
Keyphrases
- acute myeloid leukemia
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- deep learning
- machine learning
- prognostic factors
- peritoneal dialysis
- cell proliferation
- allogeneic hematopoietic stem cell transplantation
- electronic health record
- clinical trial
- randomized controlled trial
- patient reported outcomes
- single molecule
- patient reported
- data analysis
- phase iii